Legend Biotech Corp
Legend Biotech Corp is a cell therapy company focused on discovering, developing, manufacturing, and commercializing novel treatments for cancer and other serious diseases. Its core business is built around CARVYKTI®, a CAR-T therapy developed and marketed with Johnson & Johnson, alongside a pipeline of next-generation cell therapy programs.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueApproved CAR-T treatments sold through a collaboration model, centered on CARVYKTI®.
Milestone, royalty, and other non-product revenue tied to collaboration arrangements.
Investigational cell therapy candidates advancing through preclinical and clinical development.
Customers
Legend Biotech serves patients through the healthcare system, with treatment adoption driven by hematologists, oncologists, and transplant centers that administer CAR-T therapies. A major commercial counterpart is Johnson & Johnson, with whom the company collaborates on CARVYKTI® development and marketing. Its end market is the oncology treatment segment, especially patients with relapsed or refractory multiple myeloma and other difficult-to-treat cancers.
Hospitals and specialty centers that purchase and administer CARVYKTI® to eligible patients.
Patients with relapsed or refractory disease who receive CARVYKTI® as a one-time CAR-T treatment.
Strategic partner involved in development and commercialization of CARVYKTI®.
Investigators and trial sites that support testing of next-generation cell therapy assets.
Strategy
Legend Biotech is building an end-to-end cell therapy company around CARVYKTI® while expanding the product’s patient access and therapeutic reach. Its strategy also includes advancing next-generation cell therapy modalities beyond multiple myeloma, including work aimed at harder-to-treat solid tumors. Collaboration with Johnson & Johnson remains central because it broadens commercialization capacity and supports market penetration.
CARVYKTI® is the company’s core commercial asset and the main driver of adoption.
Pipeline breadth reduces dependence on one product and supports long-term growth.
The Johnson & Johnson partnership improves commercialization reach and development scale.
Geography
Legend Biotech is centered in the United States, where it develops and commercializes its core therapy and anchors most of its operating footprint. Its commercialization reach extends into Europe and Japan through CARVYKTI® approvals, while development activity also includes regulatory pathways in China. Because its business is tied to global oncology approvals and clinical sites, geography affects market access, launch timing, and regulatory execution.
Risks
Legend Biotech depends heavily on the clinical, regulatory, and commercial success of CARVYKTI®, so any disruption to uptake, manufacturing, or safety perception can affect the business materially. Cell therapy development is also scientifically and operationally complex, with long development cycles, uncertain trial outcomes, and significant dependence on specialized manufacturing and treatment infrastructure. Global approvals and reimbursement dynamics add region-specific execution risk, especially where access and launch timing vary by market.
- Product concentration in CARVYKTI®Impact: HighLikelihood: High
A large share of the business is tied to one commercial therapy.
Exposure: Commercial revenue and market valuation
- Clinical development uncertaintyImpact: HighLikelihood: Medium
Pipeline candidates may fail in preclinical or clinical testing.
Exposure: Next-generation cell therapy programs
- Manufacturing and supply chain executionImpact: HighLikelihood: Medium
CAR-T therapies require specialized manufacturing, logistics, and chain-of-custody controls.
Exposure: Autologous cell therapy delivery
- Collaboration dependenceImpact: MediumLikelihood: High
Commercialization and development are partly shared with Johnson & Johnson.
Exposure: CARVYKTI® development and marketing
- Regulatory and market access delaysImpact: MediumLikelihood: Medium
Approvals, label expansion, and reimbursement differ across regions.
Exposure
Accounting
Judgemental itemsRevenue depends on partner arrangements, milestones, and performance obligations.
Impact: Can shift revenue between quarters and affect comparability
One-time or contingent payments may be recognized when criteria are met.
Impact: Can create lumpy revenue patterns
Clinical and manufacturing development costs are a major operating line.
Impact: Affects operating loss and investment intensity
Operations and approvals span multiple currencies and jurisdictions.
Impact: Can affect reported comprehensive income
Similar listed companies
Publicly listed companies with a comparable business focus.
Cellectis S.A.
CLLS · Biological Products, (No Diagnostic Substances)
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
Lyell Immunopharma, Inc.
LYEL · Pharmaceutical Preparations
Lyell Immunopharma is a U.S.-based late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies for cancer.
Nkarta, Inc.
NKTX · Pharmaceutical Preparations
Allogene Therapeutics, Inc.
ALLO · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease.
BioNTech SE
BNTX · Biological Products, (No Diagnostic Substances)
BioNTech SE is a biotechnology company focused on discovering and developing immunotherapies and other medicines, with a major commercial base in COVID-19 vaccines and a growing oncology pipeline.
Last updated: 28/09/2026